Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

Rosenstock Julio; Aronson Ronnie; Grunberger George; Hanefeld Markolf; Piatti PierMarco; Serusclat Pierre; Cheng Xi; Zhou Tianyue; Niemoeller Elisabeth; Souhami Elisabeth; Davies Melanie

首页> 外文期刊>Diabetes care >Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

【24h】

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

机译：LixiLan的可滴定固定比例胰岛素对照与口服药物控制不充分的2型糖尿病的利西拉肽，利西拉肽和利西拉肽单组分的可计量固定比例组合的益处：LixiLan-O随机试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

OBJECTIVE

机译：目的

著录项

来源
《Diabetes care》 |2016年第11期|共10页
作者
Rosenstock Julio; Aronson Ronnie; Grunberger George; Hanefeld Markolf; Piatti PierMarco; Serusclat Pierre; Cheng Xi; Zhou Tianyue; Niemoeller Elisabeth; Souhami Elisabeth; Davies Melanie;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial [J] . Rosenstock Julio, Aronson Ronnie, Grunberger George, Diabetes care . 2016,第11期

机译：LixiLan的可滴定固定比例胰岛素对照与口服药物控制不充分的2型糖尿病的利西拉肽，利西拉肽和利西拉肽单组分的可计量固定比例组合的益处：LixiLan-O随机试验
2. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial [J] . Rosenstock Julio, Diamant Michaela, Aroda Vanita R., Diabetes care . 2016,第9期

机译：二甲双胍单药治疗控制不佳的2型糖尿病患者利西拉来定与胰岛素甘草碱的可滴定固定比例联合利西拉来的疗效和安全性：利西兰概念验证的随机试验
3. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial [J] . Diabetes care . 2020,第6期

机译：疗效和安全性为1：1胰岛素狼氨酰胺和Lixisenatide与日本2型糖尿病患者的Lixisenatide在口腔抗糖尿病药物上不充分控制：Lixilan JP-O1随机临床试验
4. TITLE: 6-month administration of Oral Insulin at Lunchtime in Juvenile Type-1 DM Subjects on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin [C] . Jaime Guevara-Aguirre, Marco Guevara-Aguirre, Jeannette Saavedra, Controlled Release Society Annual Meeting and Exposition . 2007

机译：标题：午餐时间为1型DM少年受试者接受基础甘草碱胰岛素和早餐前和晚餐前常规胰岛素的口服胰岛素治疗，为期6个月
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. Erratum. Benefits of LixiLan a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035 [O] . Julio Rosenstock, Ronnie Aronson, George Grunberger, 2017

机译：勘误表。 LixiLan（一种可滴定比例的固定剂量组合胰岛素甘精胰岛素和Lixisenatide相对于胰岛素Glargine和Lixisenatide单组分在口服药物控制不充分的情况下的益处）：LixiLan-O随机试验。 2016年糖尿病护理； 39：2026-2035
7. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. [O] . Rosenstock, J., Aronson, R., Grunberger, G., 2016

机译：LixiLan的可滴定固定比例胰岛素口服组合物的可控固定比例组合在口服药物控制不充分的2型糖尿病中的作用与胰岛素甘草碱和Lixisenatide单组分的比较：LixiLan-O随机试验。

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

摘要

著录项

相似文献

相关主题

期刊订阅